Zymeworks Announces Participation in Upcoming Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Zymeworks (ZYME) will participate in two healthcare investor conferences in Miami, where management will hold one-on-one meetings and join fireside chats.
The Evercore Healthcare Conference chat is on November 30 at 2:10 p.m. ET, and the Citi Global Healthcare Conference chat is on December 1 at 3:40 p.m. ET. Select chats will be webcast live in the Investors section of the company’s website, with replays available after the events.
AI-generated analysis. How Rhea-AI works. Not financial advice.
VANCOUVER, British Columbia, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced will participate in the following upcoming investor conferences:
- Evercore Healthcare Conference: Management will participate in one-on-one meetings and a fireside chat on November 30 at 2:10 pm Eastern Time (ET) in Miami, FL
- Citi’s 2026 Global Healthcare Conference: Management will participate in one-on-one meetings and a fireside chat on December 1 at 3:40 pm ET in Miami, FL
A live webcast of certain fireside chats will be available in the Investors section of the Zymeworks website at www.zymeworks.com, and a replay will be available following the events.
About Zymeworks Inc.
Zymeworks is a global biotechnology company building a diversified portfolio of healthcare assets designed to generate durable cash flows while advancing innovative medicines for difficult-to-treat diseases. The Company’s asset and royalty aggregation strategy combines a growing portfolio of commercial and near-commercial assets, including YUPELRI® (revefenacin), with a differentiated internal research and development engine. Zymeworks’ portfolio also includes Ziihera® (zanidatamab-hrii), a HER2-targeted bispecific antibody discovered and developed by Zymeworks and commercialized through global partnerships with Jazz Pharmaceuticals and BeOne Medicines, and pasritamig, a clinical-stage multispecific antibody developed by Johnson & Johnson using Zymeworks’ proprietary antibody engineering technologies.
Zymeworks is advancing a diverse pipeline of novel biotherapeutics, leveraging its proprietary Azymetric™ platform and expertise in antibody-drug conjugates, multispecific antibodies and other next-generation antibody technologies. These capabilities, together with Zymeworks’ integrated drug development expertise, enable the Company to develop differentiated therapeutics and create value through both internal innovation and strategic partnerships.
For more information about Zymeworks, its portfolio and pipeline, visit www.zymeworks.com and follow @ZymeworksInc on X.
Contacts:
Investor Inquiries:
Shrinal Inamdar
Vice President, Investor Relations
(604) 678-1388
ir@zymeworks.com
Media Inquiries:
Diana Papove
Vice President, Corporate Communications
(604) 678-1388
media@zymeworks.com